G protein-coupled receptors (GPCRs) are essential for cell signal transduction and comprise the largest drug target protein family. Upon agonist stimulation, these receptors activate multiple ...

Topline Phase 3 TRIUMPH-1 trial results show retatrutide drives a 30.3 percent body weight loss over 104 weeks of treatment.

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...

The glucagon-like peptide-1 (GLP-1) receptor is expressed in specialized neuronal subsets and glial cells widely distributed in the central nervous system 1, modulating a broad range of physiological ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...

EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and ...

The National Academies’ Forum on Neuroscience and Nervous Systems Disorders hosted a workshop on September 10, 2024, they brought together diverse perspectives to examine the promising but ...

Several peptide dual agonists of the human glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R) are in development for the treatment of type 2 diabetes, obesity and their ...

In a recent article published in Science, researchers reviewed clinical studies on the advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control. GLP-1 medications, ...

The FDA has cleared IND applications for UBT-251 injection, a long-acting triple-targeted glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP)/glucagon receptor agonist ...

When many of us think about how drugs work in the body, we may first think about how a drug gets into the body, such as a ...